Effect of non-steroidal anti-inflammatory drugs on gastric and duodenal prostaglandin concentrations in patients with Helicobacter pylori infection

Hepato-Gastroenterology

Volumn 46, Issue 26, 1999, Pages 1000-1004

  Tseng, Guan Ying ^a   Lin, Hwai Jeng ^a,b   Lin, Hsiao Yi ^a   Perng, Chin Lin ^a   Lee, Fa Yauh ^a   Lo, Wen Ching ^a   Tsay, Shyh Haw ^a   Li, Anna Senfen Yau ^a   Chang, Full Young ^a   Lee, Shou Dong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Helecobacter pylori; Non steroidal anti inflammatory drugs; Prostaglandin

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E3;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DUODENUM BIOPSY; DUODENUM MUCOSA; DUODENUM ULCER; DYSPEPSIA; FEMALE; GASTROINTESTINAL ENDOSCOPY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; STOMACH BIOPSY; STOMACH MUCOSA; STOMACH ULCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DINOPROSTONE; DUODENAL NEOPLASMS; DYSPEPSIA; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROSTAGLANDINS; STOMACH NEOPLASMS;

EID: 0032938016     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. 1 Tytgat GJN, Rauws EAJ: Campylobacter pylori and its role in peptic ulcer disease. Gastroenterol Clin North Am 1990; 19:183-196.
2. 2 McCarthy DM: Non-steroidal anti-inflammatory drug-induced ulcers: management by traditional therapies. Gastroenterol 1989; 96:662-674.
3. 3 Wright JP, Young GO, Klaff LJ, Weerss LA, Price SK, Marks IN: Gastric mucosal prostaglandin E levels in patients with gastric ulcer disease and carcinoma. Gastroenterol 1982; 82:263-267.
4. 4 Konturek SJ: Actions of nonsteroid anti-inflammatory compounds on gastric mucosal integrity and prostaglandin formation in healthy subjects and peptic ulcer patients. Adv Inflammation Res 1984; 6:29-37.
5. 5 Hawkey CJ, Kampton DS: Prostaglandins and the gastrointestinal mucosa: Are they important in its function, disease, or treatment? Gastroenterol 1985; 89:1162-1188.
6. 6 Crampton JR, Gibbons LC, Rees WDW: Simultaneous measurement of in vitro gastroduodenal prostaglandin E2 synthesis and degradation in peptic ulcer disease. Scand J Gastroenterol 1987; 22:425-430.
7. 7 Calabro A, Orsini B, Fedi P, et al: Enzyme immunoassay of gastric luminal prostaglandin E2 in duodenal ulcer disease. Am J Gastroenterol 1989; 84:629-632.
8. 8 Hawkey CJ: Synthesis of prostaglandin E2, thromboxane B2 and prostaglandin catabolism in gastritis and gastric ulcer. Gut 1986; 27:1482-1492.
9. 9 Bukhave K, Rask-Madsen J, Hogan DL, et al: Proximal duodenal prostaglandin E2 release and mucosal bicarbonate secretion are altered in patients with duodenal ulcer, Gastroenterol 1990; 99:951-955.
10. 10 Kataoka TM, Fujisaki J, Yasuda ESH, et al: Healing of chronic gastric ulcer depends on gastric mucosal prostaglandin synthesis. Hepato-Gastroenterol 1994; 41:111-115.
11. 11 Cryer B, Faust TW, Goldschmiedt M, et al: Gastric and duodenal mucosal prostaglandin concentrations in gastric or duodenal ulcer disease: Relationships with demographics, environmental, and histological factors, including Helicobacter pylori. Am J Gastroenterol 1992; 87:1747-1754.
12. 12 Selling JA, Hogan DL, Aly A, et al: Indomethacin inhibits duodenal mucosal bicarbonate secretion and endogenous prostaglandin E2 output in human subjects. Ann Intern Med 1987; 106:368-371.
13. 13 Cryer B, Goldschmiedt M, Redfern JS, et al: Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterol 1990; 99:1616-1621.
14. 14 Hudson N, Balsitis M, Filipowicz F, et al: Effect of Helicobacter pylori colonization on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34:748-751.
15. 15 Oderda G, Alessandro MD, Marinani P, et al: Prostaglandin E2 in gastric mucosa of children with Helicobacter pylori gastritis: relation to thickness of mucus gel layer. J Clin Pathol 1993; 46:836-839.
16. 16 Mertz-Nielsen A, Hillingso J, Frokiaer H, et al: Gastric bicarbonate secretion and release of prostaglandin E2 are increased in duodenal ulcer patients but not in Helicobacter pylori-positive healthy subjects. Scand J Gastroenterol 1996; 31:38-43.
17. 17 Konda Y, Nishisaki H, Nakano O, et al: Prostaglandin protects isolated guinea pig chief cells against ethanol injury via an increase in diacylglycerol. J Clin Invest 1990; 86:1897-1903.
18. 18 Cryer B, Redfern JS, Goldschmiedt M, et al: Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterol 1992; 102:1118-1123.
19. 19 Bode C, Maute G, Bode JC: Prostaglandin E2 and Prostaglandin F2a biosynthesis in human gastric mucosa: effect of chronic alcohol misuse. Gut 1996; 39:348-352.
20. 20 Taha AS, Boothman P, FIMLS, et al: Gastric mucosal prostaglandin synthesis in the presence of Campylobacter pylori in patients with gastric ulcers and non-ulcer dyspepsia. Am J Gastroenterol 1990; 85:47-50.
21. 21 Silecchia G, Spaziani E, Guarino E, et al: Effect of nizatidine versus ranitidine on gastric intraluminal prostaglan release in duodenal ulcer patients. Scand J Gastroenterol 1994; 29(Suppl 206):8-13.
22. 22 Laine L, Peterson WL: Bleeding peptic ulcer. N Engl J Med 1994: 331:717-727.
23. 23 Griffin MR, Ray WA, Schaffner W: Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109:359-363.
24. 24 Hovet J, Terriere L, Van Hee W, et al: Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study. Gut 1991; 32:730-734.
25. 25 Graham DY: Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: Where we stand. Am J Gastroenterol 1996; 91:2080-2086.
26. 26 Laine L, Marin-Sorensen M, Weinstein WM: Nonsteroidal anti-inflammatory drug associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 1992; 87:1398-1402.
27. 27 Bianchi Porro G, Parente F, Imbesi V, et al: Role of Helicobacter pylori in ulcer healing and recurrence and recurrence of gastric and duodenal ulcers in long-term NSAID users. Response to omeprazole dual therapy. Gut 1996; 39:22-26.
28. 28 Lam SK, Talley NJ: Helicobacter pylori consensus. Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13:1-12.
29. 29 Li EKM, Chan FKL, Sung JJY, et al: Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350:975-979.
30. 30 Cryer B, Lee E, Feldman M: Factors influencing gastroduodenal mucosal prostaglandin concentrations: Roles of smoking and aging. Ann Intern Med 1992; 116:636-640.
31. 31 Lindell G, Bukhave K, Lilja I, et al: Acute effects of high-dose intragastric nicotine on mucosal defense mechanisms. Dig Dis Sci 1997; 42:640-644.
32. 32 The European Helicobacter Pyolri Study Group: Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 1997; 41:8-13.
33. 33 Price AB, The Sydney System: A non classification of gastritis: a histological division. J Gastroenterol Hepatol 1998; 6:209-222.